Stock Market & Financial Investment News

News Breaks March 14, 2013 07:07 EDT LGND, SPPI Ligand Pharmaceuticals and Spectrum sign global melphalan license agreement Ligand Pharmaceuticals (LGND) signed global license and supply agreements with Spectrum (SPPI) for the development and commercialization of Ligand’s Captisol-enabled, propylene glycol-free melphalan. Ligand is entitled to receive a license fee and is eligible to receive more than $50M in potential milestone payments. Ligand is also eligible to receive royalties on future net sales of Captisol-enabled melphalan. News For LGND;SPPI From The Last 14 Days Check below for free stories on LGND;SPPI the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 24, 2013 07:26 EDT LGND Ligand Pharmaceuticals management to meet with Roth Capital Meeting to be held in Boston on May 30 hosted by Roth Capital. May 15, 2013 19:34 EDT SPPI On The Fly: After Hours Movers Subscribe for More Information 11:16 EDT SPPI Options with decreasing implied volatility: RAX CSC SPPI MBI PANL 11:06 EDT LGND Ligand Pharmaceuticals management to meet with Roth Capital Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.